Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucatinib in HER2+ Advanced Cancers (China)
NCT05382364Phase 1Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jun 2022
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of tucatinib in breast cancer, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and 1 more, sponsored by Pfizer. Primary endpoints: Percentage of participants with ≥1 adverse event at 2.5 years and Percentage of participants discontinuing from study therapy due to AE at 2.5 years. Started Jun 2022; status: active, not recruiting.
02
Drugs
tucatinib
03
Conditions
breast cancergastric adenocarcinomagastroesophageal junction adenocarcinomacolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05382364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05382364.